Enzychem Lifesciences Corporation

Enzychem Lifesciences Corporation develops novel small molecule therapeutics for patients with unmet needs in oncology, inflammatory, and severe respiratory diseases. It is also developing EC-18, an oral small molecule for fibrotic diseases such as nonalcoholic steatohepatitis, and as a potential therapy for COVID-19 in severe respiratory diseases. The company was founded in 1999 and is headquartered in Seoul, South Korea.